TABLE 7.

Anti-CT antibody titer versus postchallenge stool volume and fold increase in anti-CT antibody titer versus postchallenge stool volume by treatment in the group challenged at 90 days

Assessment	Vaccine group		Placebo group
	No. of subjects	Mean (median) total stool volume (liters)	No. of subjects	Mean (median) total stool volume (liters)
Day 28 anti-CT antibody titer
10–399	6	0.8 (0.3)	23	4.9 (4.5)
400–1,599	11	2.1 (0.2)	6	7.7 (5.3)
1,600–6,399	8	0.3 (0.2)	2	4.1 (4.1)
6,400+	8	0.8 (0.5)	2	5.9 (5.9)
Fold increase in anti-CT antibody titer from day 0 to day 28
≤3.9	10	2.5 (0.3)	32	5.2 (4.6)
4–7.9	4	0.5 (0.3)	1	11.2 (11.2)
8–15.9	9	0.7 (0.2)
16+	10	0.3 (0.2)